U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Richard Pazdur, Joyce Cheng et al.|Clinical Cancer Research|2018Cited by 98
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safetyJohn L. Hays, Elise C. Kohn, Geoff Kim et al.|Molecular and Clinical Oncology|2013Cited by 36
An Integrated Program in a Pandemic: Johns Hopkins Radiation Oncology DepartmentJean L. Wright, Akila Viswanathan, Sara R. Alcorn et al.|Advances in Radiation Oncology|2020Cited by 17
Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp TrialElizabeth A. Hahn, Harald Paganetti, Stephanie L. Pugh et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 3
Impact of Breast volume, Body Mass Index, and Treatment Position on Heart and Lung Dose and Development of Acute Toxicities in Hypofractionated Whole Breast IrradiationAbhinav V. Reddy, Sara R. Alcorn, Jean L. Wright et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 0